Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will be presenting on March 9, 2022, at the Raymond James Institutional Investors Conference in Orlando, Florida.

Simulations Plus to Present at Raymond James Institutional Investors Conference

Simulations Plus, Inc. is a premier developer of modeling and simulation software for drug discovery and development.

Simulations Plus: Software For The Pharma Industry, Significant Upside Potential

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will be presenting on Feb 15, 2022, at BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus enters another new funded collaboration to enhance GastroPlus and advance research into new treatments for gastrointestinal diseases.

Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that a new funded collaboration will enhance GastroPlus to support veterinary medicine and alternatives to animal testing.

Simulations Plus Enters New Collaboration with Leading Animal Health Company

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO Shawn O'Connor will be presenting and meeting investors at the virtual Sidoti Winter Small Cap Investor Conference, Jan. 19-20.

Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference

Simulations Plus (SLP) Q1 results benefit from a rebound in the Services business. Software business revenues continue to witness strong growth.

Simulations Plus (SLP) Q1 Earnings & Revenues Beat Estimates

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2022 Results - Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of 36.36% and 11.19%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Q1 Earnings and Revenues Top Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports total revenue of $12.4 million, up 16%, for the 1st quarter of FY22 with software revenue of $7.4 million, up 19% over FY21.

Simulations Plus Reports First Quarter Fiscal 2022 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases MonolixSuite 2021R1 with several important features including a powerful and easy-to-use Bioequivalence Module in PKanalix.

Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1

Simulations Plus (SLP) fiscal first-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus and ADMET predictor.

What to Expect Ahead of Simulations Plus (SLP) Q1 Earnings?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report 1st quarter fiscal year 2022 financial results, on Thu., Jan. 6, 2022, with a webcast at 5pm ET.

Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--MonolixSuite has been added to the Simulations Plus suite of software applications distributed in Japan by Northern Science Consulting.

Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™

NASHVILLE, Tenn., Nov. 30, 2021 /PRNewswire/ -- Simulations Plus (NASDAQ: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the Dispensary of Hope.

Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus donates $25,000 to Dispensary of Hope, a national nonprofit devoted to delivering high-quality medication to underserved communities

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that Sharlene Evans, a proven leader, has joined the Company's Board of Directors replacing the retiring Dr. David Ralph.

Simulations Plus Names Sharlene Evans to Board of Directors

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus presented results from its QSP model NAFLDsym showing the impact of yo-yo dieting on placebo response rates in NASH clinical trials.

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of RENAsym version 1A, its novel QST software for predicting and investigating drug-induced kidney injury.

Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury

GastroPlus & ADMET Predictor software continue to drive gains for the company.

Simulations Plus: Ample Momentum In Software Segment To Drive More Gains

Comcast

Cintas Corp

Estee Lauder

NIKE

NVIDIA

Sherwin-Williams

S&P Global

Sun Communities

Texas Pacific Land Trust

When picking winners for the next decade plus, projections can only take you so far. These 10 stocks to buy sweeten the deal with dividends.

10 Long-term Stocks to Buy for the Next 15 Years

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus has released version 9.8.2 of its flagship GastroPlus PBBM/PBPK modeling program with essential new models, options, and workflows.

Simulations Plus Releases GastroPlus® Version 9.8.2

Craig-Hallum has upgraded Simulations Plus Inc (NASDAQ: SLP) to Buy from Hold with a price target of $53, down from $65.  Related:   Simulations Plus Target Price Lowered At Craig-Hallum, Raymond James After Q3 Sales Miss Expectations.

Why Did Craig-Hallum Upgrade Simulations Plus After Q4 Earnings?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new FDA-funded grant award with the University of Connecticut to enhance mechanistic models for long-acting injectables.

Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q4 2021 Results - Earnings Call Transcript

News for Simulations Plus Stock (SLP)